Sight Sciences (SGHT)
(Delayed Data from NSDQ)
$5.82 USD
+0.54 (10.23%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $5.82 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SGHT 5.82 +0.54(10.23%)
Will SGHT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SGHT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SGHT
Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue Estimates
Sight Sciences (SGHT) to Expand in Europe With New Launch
SGHT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ekso Bionics (EKSO) Reports Q3 Loss, Tops Revenue Estimates
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates
ConforMIS (CFMS) Reports Q2 Loss, Tops Revenue Estimates
Other News for SGHT
Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery
Sight Sciences announces $34M patent infringement verdict against Alcon
Sight Sciences to Report First Quarter Financial Results on May 2, 2024
Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNIĀ® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC) and Sight Sciences (SGHT)